Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) concerning whether the board breached its fiduciary duties to shareholders.
IF YOU ARE A RXSIGHT, INC. (RXST) SHAREHOLDER, CLICK HERE TO PARTICIPATE.
What Is the Investigation About?
On July 8, 2025, after the market closed, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in LDD sales, LAL utilization, and overall revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint. The Company’s Chief Executive Officer, Ronald Kurtz, disclosed that “[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.”
